Tower Research Capital LLC TRC Has $70,000 Stock Position in STAAR Surgical (NASDAQ:STAA)

Tower Research Capital LLC TRC reduced its holdings in STAAR Surgical (NASDAQ:STAA) by 53.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 2,885 shares of the medical instruments supplier’s stock after selling 3,376 shares during the quarter. Tower Research Capital LLC TRC’s holdings in STAAR Surgical were worth $70,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in shares of STAAR Surgical by 411.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock valued at $7,978,000 after purchasing an additional 172,779 shares during the last quarter. Defender Capital LLC. boosted its stake in STAAR Surgical by 3.5% during the fourth quarter. Defender Capital LLC. now owns 701,567 shares of the medical instruments supplier’s stock worth $17,041,000 after acquiring an additional 23,950 shares in the last quarter. KBC Group NV lifted its stake in shares of STAAR Surgical by 5,700.9% in the fourth quarter. KBC Group NV now owns 96,585 shares of the medical instruments supplier’s stock valued at $2,346,000 after buying an additional 94,920 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of STAAR Surgical in the fourth quarter valued at $923,000. Finally, Barclays PLC lifted its stake in shares of STAAR Surgical by 349.4% in the third quarter. Barclays PLC now owns 91,707 shares of the medical instruments supplier’s stock valued at $3,406,000 after buying an additional 71,301 shares in the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Canaccord Genuity Group increased their price target on STAAR Surgical from $17.00 to $20.00 and gave the company a “hold” rating in a research report on Thursday. William Blair lowered STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. Wells Fargo & Company started coverage on STAAR Surgical in a report on Monday, April 21st. They set an “equal weight” rating and a $17.00 price objective for the company. Piper Sandler reduced their price objective on STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, February 12th. Finally, BTIG Research lowered STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, STAAR Surgical presently has a consensus rating of “Hold” and an average target price of $24.63.

Insider Buying and Selling

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 36,532 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were acquired at an average cost of $15.49 per share, with a total value of $565,880.68. Following the transaction, the insider now owns 11,289,437 shares of the company’s stock, valued at $174,873,379.13. The trade was a 0.32% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have purchased 1,742,581 shares of company stock worth $28,407,543 in the last 90 days. Insiders own 1.00% of the company’s stock.

STAAR Surgical Stock Performance

STAA stock opened at $19.36 on Monday. STAAR Surgical has a fifty-two week low of $13.50 and a fifty-two week high of $49.86. The business’s 50 day moving average price is $17.57 and its two-hundred day moving average price is $21.86. The company has a market capitalization of $958.82 million, a price-to-earnings ratio of -47.22 and a beta of 0.65.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.